US Stock Insider Trading | Natera disclosed 6 insider transactions on March 11

K-LinePoet · 2026-04-02T14:16:36+00:00

On March 11, 2026, Natera disclosed that several internal executives conducted stock sales on March 10, including Director Chapman Steven Leonard selling 5,623 shares for a total of $1,147,800. Natera is a diagnostic company dedicated to transforming disease management using advanced molecular technologies.

K-LinePoet

2026-04-02 14:16:36

Abstract generation in progress

On March 11, 2026, Natera (NTRA) disclosed six corporate insider transactions. Director Chapman Steven Leonard sold 5,623 shares on March 10, 2026.

[Recent Insider Transactions]

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share / USD	Total amount / USD
March 11, 2026	Executive	Fesko John	March 10, 2026	Sold	707	204.13	144.3K
March 11, 2026	Executive	Brophy Michael Burkes	March 10, 2026	Sold	785	204.13	160.2K
March 11, 2026	Executive	Moshkevich Solomon	March 10, 2026	Sold	915	204.13	186.8K
March 11, 2026	Executive	RABINOWITZ DANIEL	March 10, 2026	Sold	1,745	204.13	356.2K
March 11, 2026	Director	Sheena Jonathan	March 10, 2026	Sold	127	204.13	25.9K
March 11, 2026	Director	Chapman Steven Leonard	March 10, 2026	Sold	5,623	204.13	1.1478M
March 10, 2026	Executive	RABINOWITZ DANIEL	March 6, 2026	Sold	1,998	198.04	395.7K
March 10, 2026	Executive	RABINOWITZ DANIEL	March 6, 2026	Sold	1,600	195.80	313.3K
March 10, 2026	Executive	RABINOWITZ DANIEL	March 6, 2026	Sold	400	193.73	77.5K
March 10, 2026	Executive	RABINOWITZ DANIEL	March 6, 2026	Bought	5,598	19.68	110.2K

[Company Profile]

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostics company with proprietary molecular and bioinformatics technologies. It is applying this technology to change disease management worldwide. The company’s cell-free DNA (CFDNA) technology combines novel molecular analysis methods that can reliably measure many information regions across the entire genome from samples ranging from small quantities to individual-cell samples, as well as statistical algorithms. These algorithms combine data provided by the broader scientific community to identify genetic variants associated with a wide range of serious diseases with high precision and high coverage. The company’s goal is to make personalized genetic testing and diagnostics part of the standard of care that protects health, and to inform earlier and more targeted interventions to help achieve a longer, healthier life.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.